MedTrace Logo

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

NCT05100082 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2025-12-30

No results posted yet for this study

Summary

This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.

Conditions

  • Hepatocellular Cancer

Interventions

DRUG

Cabozantinib

Cabozantinib tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-17
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05100082 on ClinicalTrials.gov